Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 …

Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 …

With no approved therapy for the treatment of brain metastases, options for this patient population are currently limited,” said Erika Hamilton, M.D., director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute. “This

(Visited 5 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.